Dr Ed Schwalbe Dr Janet Lindsey Dr Marina Danilenko Dr Rebecca Hill Dr Stephen Crosier et al. | Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: A multicenter cohort study | 2025 |
|
Dr Marion Mateos Dr Daniel Williamson Dr Marina Danilenko Dr Jack Goddard Dr Stephen Crosier et al. | MDB-64. Novel transcripts associate with survival in childhood medulloblastoma. | 2024 |
|
Dr Florence Burté Magretta Adiamah Dr Fatma Scerif Dr Debbie Hicks Dr Ed Schwalbe et al. | Metabolite profiles of medulloblastoma for rapid and non-invasive detection of molecular disease groups | 2024 |
|
James Hacking Dr Dean Thompson Dr Ed Schwalbe Professor Steven Clifford Dr Daniel Williamson et al. | Deriving a continuum score for group 3 and 4 medulloblastoma tumor samples analyzed via RNA-sequencing or DNA methylation microarray | 2023 |
|
Dr Jack Goddard Jemma Castle Emily Southworth Anya Fletcher Dr Stephen Crosier et al. | Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification | 2023 |
|
Dr Daniel Williamson
| The proteomic landscape of soft tissue sarcomas | 2023 |
|
Dr Daniel Williamson Dr Ed Schwalbe Professor Simon Bailey Professor Steven Clifford
| Timing is everything: A connection between medulloblastoma prognosis and foetal cerebellar development | 2023 |
|
Dr Daniel Williamson Professor Steven Clifford
| Beta-blockers disrupt mitochondrial bioenergetics and increase radiotherapy efficacy independently of beta-adrenergic receptors in medulloblastoma | 2022 |
|
Dr Stacey Richardson Dr Rebecca Hill Dr Christopher Kui Dr Janet Lindsey Dr Yura Grabovska et al. | Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse | 2022 |
|
Dr Ricky Tirtakusuma Dr Katarzyna Szoltysek Professor Vasily Grinev Dr Sirintra Nakjang Dr Daniel Williamson et al. | Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia | 2022 |
|
Dr Yura Grabovska Dr Daniel Williamson
| Erratum: Molecular subgrouping of atypical teratoid/rhabdoid tumors - a reinvestigation and current consensus (Neuro-Oncology DOI: 10.1093/neuonc/noz235) | 2022 |
|
Dr Jack Goddard Jemma Castle Emily Southworth Anya Fletcher Dr Stephen Crosier et al. | MEDB-71. Molecular characterisation of Group 4 medulloblastoma improves risk-stratification and its biological understanding | 2022 |
|
Dr Daniel Williamson Dr Ed Schwalbe Dr Debbie Hicks Dr Janet Lindsey Dr Stephen Crosier et al. | Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar development | 2022 |
|
Dr Marina Danilenko Dr Claire Keeling Dr Stephen Crosier Dr Martina Finetti Dr Daniel Williamson et al. | Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development | 2022 |
|
Dr Stephen Crosier Dr Debbie Hicks Dr Ed Schwalbe Dr Daniel Williamson Amanda Smith et al. | Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnostics | 2021 |
|
Dr Debbie Hicks Dr Reza Rafiee Dr Ed Schwalbe Dr Christopher Howell Dr Janet Lindsey et al. | The molecular landscape and associated clinical experience in infant medulloblastoma: prognostic significance of second-generation subtypes | 2021 |
|
Dr Matthew Selby Dr Daniel Williamson Professor Steven Clifford
| Erratum: Author Correction: VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells (Communications biology (2020) 3 1 (579)) | 2020 |
|
Dr Martina Finetti Dr Daniel Williamson
| Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors | 2020 |
|
Yura Grabovska Dr Daniel Williamson
| Molecular subgrouping of Atypical Teratoid/Rhabdoid Tumors (ATRT) – a reinvestigation and current consensus | 2020 |
|
Dr Yura Grabovska Dr Stephen Crosier Dr Martina Finetti Dr Ed Schwalbe Dr Rebecca Hill et al. | Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity | 2020 |
|
Dr Rebecca Hill Dr Stacey Richardson Dr Ed Schwalbe Dr Debbie Hicks Dr Janet Lindsey et al. | Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study | 2020 |
|
Dr Martina Finetti Yura Grabovska Professor Simon Bailey Dr Daniel Williamson
| Translational Genomics of Malignant Rhabdoid Tumours: Current Impact and Future Possibilities | 2020 |
|
Dr Martina Finetti Dr Daniel Williamson
| Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation | 2019 |
|
Dr Rebecca Hill Professor Steven Clifford Yura Grabovska Dr Daniel Williamson
| DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study | 2019 |
|
Dr Ed Schwalbe Dr Daniel Williamson Dr Janet Lindsey Dr Rebecca Hill Dr Debbie Hicks et al. | Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes | 2019 |
|
Dr Daniel Williamson Dr Christopher Jones Professor Steven Clifford
| Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group | 2018 |
|
Dr Ed Schwalbe Dr Debbie Hicks Dr Reza Rafiee Dr Matthew Bashton Dr Amir Enshaei et al. | Minimal methylation classifier (MIMIC): A novel method for derivation and rapid diagnostic detection of disease-associated DNA methylation signatures | 2017 |
|
Dr Ed Schwalbe Dr Janet Lindsey Dr Sirintra Nakjang Dr Stephen Crosier Amanda Smith et al. | Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study | 2017 |
|
Dr Matthew Selby Dr Daniel Williamson Professor Steven Clifford
| TAp73 is a marker of glutamine addiction in medulloblastoma | 2017 |
|
Dr Stephen Crosier Dr Debbie Hicks Dr Ed Schwalbe Dr Daniel Williamson Sarah Nicholson et al. | Centralised Molecular Pathology for Rare Tumours: A National Feasibility Study of Real-Time Medulloblastoma Diagnostics | 2016 |
|
Dr Al Gabriel Dr Lindi Chen Dr Sirintra Nakjang Dr Daniel Williamson Professor Deborah Tweddle et al. | Combined Copy Number and Gene Expression Profiling in High Rick Neuroblastoma: A CCLG Pilot Biological Study | 2016 |
|
Dr Martina Finetti Dr Stephen Crosier Dr Daniel Williamson
| Dual Targeting of PDGFR alpha and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors | 2016 |
|
Dr Debbie Hicks Dr Ed Schwalbe Dr Stephen Crosier Professor Simon Bailey Dr Daniel Williamson et al. | Identification of medulloblastoma molecular subgroups using metabolite profiles | 2016 |
|
Dr Martina Finetti Matthew Selby Dr Matthew Bashton Dr Ruth Cranston Dr Stephen Crosier et al. | Integrated pathway analysis of malignant rhabdoid tumour identifies key SMARCB1-pathways and therapeutic opportunities | 2016 |
|
Dr Martina Finetti Alicia Del Carpio Pons James Barker James Wood Dr Sirintra Nakjang et al. | Integrated pathway analysis of rhabdoid tumor subtypes identifies key SMARCB1-dependencies and therapeutic opportunities | 2016 |
|
Matthew Selby Dr Martina Finetti Dr Matthew Bashton Dr Ruth Cranston Alicia Del Carpio Pons et al. | Investigating the biology of atypical teratoid/rhabdoid tumors by whole genome CRISPR/CAS9 screening | 2016 |
|
Dr Janet Lindsey Dr Rebecca Hill Dr Ed Schwalbe Dr Christopher Howell Dr Reza Rafiee et al. | Molecular and Prognostic Heterogeneity within MYC and MYCN Amplified Medulloblastomas | 2016 |
|
Dr Ed Schwalbe Dr Debbie Hicks Dr Reza Rafiee Dr Matthew Bashton Dr Amir Enshaei et al. | Routine Diagnostic Medulloblastoma Subgrouping Using Low-Cost, Low-Input DNA Methylomics: Application to Trials Cohorts Previously Refractory-to-Analysis | 2016 |
|
Dr Ed Schwalbe Dr Debbie Hicks Dr Reza Rafiee Dr Matthew Bashton Dr Amir Enshaei et al. | Routine molecular subgrouping of medulloblastoma: Bridging the divide between research and the clinic using low-cost, mass spectrometry-based DNA methylomics | 2016 |
|
Dr Debbie Hicks Dr Reza Rafiee Dr Ed Schwalbe Dr Christopher Howell Dr Janet Lindsey et al. | Subgroup-Directed Stratification of Risk in Infant Medulloblastoma | 2016 |
|
Dr Daniel Williamson Dr Janet Lindsey Dr Debbie Hicks Dr Stephen Crosier Amanda Smith et al. | The Transcriptional Landscape of Medulloblastoma: Group 3 and Group 4 Tumours Comprise a Single Clinically Significant Expression Continuum | 2016 |
|
Dr Rebecca Hill Dr Janet Lindsey Dr Ed Schwalbe Dr Karen Barker Dr Daniel Williamson et al. | Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease | 2015 |
|
Dr Janet Lindsey Dr Ed Schwalbe Matthew Selby Dr James Hayden Dr Daniel Williamson et al. | Cross-species epigenetics identifies a critical role for VAV1 in SHH subgroup medulloblastoma maintenance | 2015 |
|
Dr Lindsay Nicholson Elizabeth Matheson Lynne Minto Christopher Keilty Maryna Sanichar et al. | Quantitative proteomic analysis reveals maturation as a mechanism underlying glucocorticoid resistance in B lineage ALL and re-sensitization by JNK inhibition | 2015 |
|
Dr Janet Lindsey Dr Ed Schwalbe Sandeep Potluri Professor Simon Bailey Dr Daniel Williamson et al. | TERT promoter mutation and aberrant hypermethylation are associated with elevated expression in medulloblastoma and characterise the majority of non-infant SHH subgroup tumours | 2014 |
|
Dr Martina Finetti Alicia Del Carpio Pons Ben Skalkoyannis Matthew Selby Amanda Smith et al. | A Systems Biology Approach to Identify Mechanism of Tumourigenesis Caused by Loss of SMARCB1 in Malignant Rhabdoid Tumors (BACR28) | 2014 |
|
Dr Martina Finetti Matthew Selby Dr Stephen Crosier Ben Skalkoyannis Professor Simon Bailey et al. | Characterising critical pathways in ATRT tumourigenesis: a genome-wide analysis of primary tumours and functional genomic models | 2014 |
|
Dr Janet Lindsey Dr Ed Schwalbe Dr James Hayden Professor David Ellison Dr Daniel Williamson et al. | Cross-Species Epigenetics Identifies a Critial Role for VAV1 in the Maintenance of Sonic Hedgehog Subgroup Medulloblastomas | 2014 |
|
Dr Daniel Williamson Professor Olaf Heidenreich
| Identification of a Dynamic Core Transcriptional Network in t(8;21) AML that Regulates Differentiation Block and Self-Renewal | 2014 |
|
Dr Martina Finetti Ben Skalkoyannis Matthew Selby Dr Stephen Crosier Professor Simon Bailey et al. | Mechanism of tumourigenesis caused by loss of SMARCB1 in malignant rhabdoid tumors | 2014 |
|
Professor Simon Bailey Professor Steven Clifford Dr Daniel Williamson
| Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group | 2014 |
|
Dr Rebecca Hill Dr Janet Lindsey Dr Ed Schwalbe Dr Daniel Williamson Dr Sarra Ryan et al. | MYC and TP53 defects emerge and interact at medulloblastoma relapse, define rapidly progressive disease and can be targeted therapeutically | 2014 |
|
Dr Rebecca Hill Dr Janet Lindsey Dr Ed Schwalbe Dr Karen Barker Dr Daniel Williamson et al. | MYC and TP53 defects interact at medulloblastoma relapse to define rapidly progressive disease and can be targeted therapeutically | 2014 |
|
Dr Martina Finetti Matthew Selby Alicia Del Carpio Pons Ben Skalkoyannis Amanda Smith et al. | Next-generation sequencing identifies the mechanism of tumourigenesis caused by loss of SMARCB1 in malignant rhabdoid tumours | 2014 |
|
Dr Ed Schwalbe Dr Debbie Hicks Dr Reza Rafiee Dr Amir Enshaei Sandeep Potluri et al. | Routine molecular subgrouping of medulloblastoma: Bridging the divide between research and the clinic using low-cost DNA methylomics | 2014 |
|
Dr Klaus Rehe Kerrie Wilson Dr Simon Bomken Dr Daniel Williamson Professor Julie Irving et al. | Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations | 2013 |
|
Dr Ed Schwalbe Dr Daniel Williamson Dr Janet Lindsey Dolores Hamilton Sarra Ryan et al. | DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies | 2013 |
|
Dr Daniel Williamson
| HES6 enhances the motility of alveolar rhabdomyosarcoma cells | 2013 |
|
Dr Daniel Williamson Professor Olaf Heidenreich
| Identification of a Dynamic Core Transcriptional Regulatory Network for t(8;21) AML | 2013 |
|
Dr Matthew Allen Dr Daniel Williamson Professor Steven Clifford
| Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells | 2013 |
|
Dr Sarra Ryan Dr Ed Schwalbe Mike Cole Yuan Lu Dr Meryl Lusher et al. | MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma | 2012 |
|
Dr Daniel Williamson
| PAX3/FOXO1 Fusion Gene Status is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification | 2012 |
|
Dr Daniel Williamson Professor Steven Clifford
| A significant proportion of medulloblastoma do not sub-group robustly: Identification of a molecular NOS (not otherwise specified) subgroup | 2012 |
|
Dr Daniel Williamson Professor Steven Clifford
| Biological and clinical heterogeneity of MYCN-amplified medulloblastoma | 2012 |
|
Dr Daniel Williamson Hesta McNeill Dr Michael Cullen Professor Bryan Young Professor Olaf Heidenreich et al. | Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding | 2012 |
|
Dr Daniel Williamson Professor Steven Clifford
| Dissecting the genomic complexity underlying medulloblastoma | 2012 |
|
Dr Ed Schwalbe Dr Janet Lindsey Dr Daniel Williamson Kieran O'Toole Dr Meryl Lusher et al. | Epigenetic sub-classification and risk-stratification of medulloblastoma using DNA methylomics | 2012 |
|
Dr Daniel Williamson
| Inconvenience of Convenience Cohorts-Letter | 2012 |
|
Dr Daniel Williamson
| Fusion Gene-Negative Alveolar Rhabdomyosarcoma Is Clinically and Molecularly Indistinguishable From Embryonal Rhabdomyosarcoma | 2010 |
|
Dr Daniel Williamson
| Reply to J.R. Anderson et al | 2010 |
|
Dr Daniel Williamson
| Genomic Imbalances in Rhabdomyosarcoma Cell Lines Affect Expression of Genes Frequently Altered in Primary Tumors: An Approach to Identify Candidate Genes Involved in Tumor Development | 2009 |
|
Dr Daniel Williamson
| Role for amplification and expression of Glypican-5 in rhabdomyosarcoma | 2007 |
|
Dr Daniel Williamson
| Comparative genomic hybridization and BUB1B mutation analyses in childhood cancers associated with mosaic variegated aneuploidy syndrome | 2006 |
|
Dr Daniel Williamson
| Nascent pre-rRNA overexpression correlates with an adverse prognosis in alveolar rhabdomyosarcoma | 2006 |
|
Dr Daniel Williamson
| Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR | 2006 |
|
Dr Daniel Williamson
| The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas | 2006 |
|
Dr Daniel Williamson
| Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype | 2005 |
|
Dr Daniel Williamson
| Comparative genomic hybridisation and comparative expressed sequence hybridisation as complements to microarray analyses of tumours | 2004 |
|
Dr Daniel Williamson
| Expression profiling targeting chromosomes for tumor classification and prediction of clinical behavior | 2003 |
|
Dr Daniel Williamson
| Comparative expressed sequence hybridization to chromosomes for tumor classification and identification of genomic regions of differential gene expression | 2001 |
|